Related Experiment Video
Updated: May 3, 2026
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 18, 2014
Growing Challenges of Lung Infections with Non-tuberculous Mycobacteria in Immunocompromised Patients: Epidemiology
Weronika Burzyńska1, Marek Fol1, Magdalena Druszczynska1
1Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Abstract:
Non-tuberculous mycobacteria (NTM) are increasingly recognized as opportunistic pathogens in humans and animals, particularly affecting those with compromised immune systems. These bacteria encompass a diverse group of mycobacterial species that are responsible for a range of infections, with pulmonary and skin-related conditions being the most common. The rise in NTM infections in recent years is a growing concern for healthcare, highlighting the urgent need to improve our understanding of NTM epidemiology and treatment strategies. This article reviews the NTM species associated with lung infections in immunocompromised patients and underscores the critical importance of advancing diagnostic and therapeutic approaches. The review is based on a thorough analysis of scientific literature from databases such as PubMed, Scopus, and ScienceDirect, covering studies up to June 2024. Through this comprehensive analysis, the article aims to provide detailed insights into the complexities of NTM diseases and spur further research and innovation in combating these challenging infections.
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...